Moreover, transient overexpression of Bcl-2 in primary human CLL cells resulted in increased resistance to both BDA-366 and venetoclax, further suggesting that BDA-366 does not induce apoptosis by converting Bcl-2 into a proapoptotic protein (Fig. 2d and Supplementary Fig. 3A, B). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.